Education and Innovation in Cardiovascular Medicine

Consuming probiotics can reduce blood pressure

23-7-2014 • Khalesi S et al., Hypertension. 2014
Meta-analysis shows that consumption of probiotics can yield a modest reduction of systolic and diastolic blood pressure, thus probiotics may be used to improve BP control. Read more

Monotherapy with PCSK9-antibody superior to ezetimibe in hypercholesterolaemia

21-7-2014 • Roth EM et al., Int J Cardiol. 2014
Phase III study shows that monotherapy with alirocumab, a PCSK9 antibody, is more effective at lowering LDL-c than ezetimibe, in patients with hypercholesterolaemia and moderate CV risk. Read more
News • 21-7-2014

Promising results of treatment of secondary hyperparathyroidism in chronic kidney disease

Positive results for the calcimimetic agent AMG 416 in phase III study for treatment of secondary hyperparathyroidism in patients with chronic kidney disease who receive dialysis. Read more

Depressive symptoms, chronic stress and hostility associated with increased stroke risk

15-7-2014 • Everson-Rose SA et al., Stroke. 2014
Increased stroke/TIA risk seen with depressive symptoms, chronic stress or hostility, which could not be explained by traditional stroke risk factors, inflammatory markers or subclinical atherosclerosis. Read more

Non-fasting LDL-c levels have similar predictive value for mortality as fasting levels

14-7-2014 • Doran B et al. Circulation. 2014
Analysis in large NHANES-III cohort shows that fasting LDL-c levels do not have better prognostic value for all-cause or CV mortality than the more convenient, non-fasting levels. Read more

Increased HF-related hospitalizations with sitagliptin in diabetic patients with established heart failure

7-7-2014 • Weir DL et al., JACC Heart Fail. 2014
Population-based study shows no increased risk of all-cause death or hospital admission in patients with T2D and HF, but sitagliptin was associated with increase in HF-related hospital admissions. Read more

Psychostimulant treatment in children with ADHD doubles CV risk

2-7-2014 • Dalsgaard S et al., J Child Adolesc Psychopharmacol. 2014
Although CV events were rare, after stimulant treatment they were 1.8-fold more likely in the general population and 2.2-fold more likely in children and adolescents with ADHD. Read more

Raising HDL-c levels via distinct mechanisms does not lower CV morbidity and mortality

21-7-2014 • Keene D et al., BMJ. 2014
A meta-analysis of studies evaluating niacin, fibrates and CETP inhibitors shows that none of these HDL-raising agents significantly affects mortality and CV morbidity. Read more

Various sedentary behaviours differentially affect mortality risk

15-7-2014 • Basterra-Gortari FJ et al., J Am Heart Assoc. 2014
Television watching, but not computer use and time driving, were associated with all-cause mortality in the SUN cohort of Spanish University Graduates. Read more

Renal denervation persistently lowers blood pressure at least 36 months

14-7-2014 • Esler MD et al., Eur Heart J. 2014
36 months follow-up of RDN-treated patients and 30 months follow-up of RDN-treated patients who were initially in the control group of SYMPLICITY HTN-2, shows durable BP lowering effect. Read more

Improving health lifestyle in middle age lowers atherosclerosis risk

7-7-2014 • Spring B et al., Circulation. 2014
Even after a person reaches young adulthood and independent of the health lifestyle at this stage, improving lifestyle can lower the odds of coronary atherosclerosis. Read more

Many chronic inflammatory disorders associated with higher risk of CHD and diabetes

2-7-2014 • Dregan A et al., Circulation. 2014
Population-based study shows that diverse chronic inflammatory disorders were associated with an increased risk of at least two of the CHD, stroke and diabetes outcomes, possibly in a dose-responsive fashion. Read more

Upcoming meetings

CV Risk Master Class August 7, 2014, Ho Chi Minh, Vietnam
CV Risk Master Class August 9, 2014, Jakarta, Indonesia
SNAPSHOT meeting 2014 30-8-2014, Barcelona, Spain
All upcoming meetings...

Meeting reports & resources


Statin-loaded HDL nanoparticle Raphaël Duivenvoorden
CV Risk Master Class Latin American chapter Applying new insights to clinical practice
The challenge for CV Risk management in Latin America Opportunities for early intervention
All e-learning...